Current Report Filing (8-k)
22 June 2019 - 7:29AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
____________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 31, 2019
Alterola Biotech, Inc.
(Exact name of registrant as specified in its charter)
Nevada
|
333-156091
|
TBA
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
340 S Lemon Ave #4041,
Walnut CA
|
91789
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s
telephone number, including area code: 909-584-5853
_______________________
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[
]
|
Written
communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
|
|
|
[
]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. [ ]
SECTION 4-
Matters
Related to Accountants and Financial Statements
Item 4.01 Changes in Registrant’s Certifying Accountant.
On May 31, 2019, MJF & Associates (the “Former Accountant”)
resigned as the Company’s independent registered public accounting firm.
The Former Accountant’s audit report on the financial statements
of the Company for the fiscal years ended September 30, 2017 and 2016 contained no adverse opinion or disclaimer of opinion, nor
were they qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports on the financial
statements of the Company for the fiscal years ended September 30, 2017 and 2016 contained an uncertainty about the Company’s
ability to continue as a going concern.
During the fiscal years ended September 30, 2017 and 2016, and through
the interim period ended May 31, 2019, there were no “disagreements” (as such term is defined in Item 304 of Regulation
S-K) with the Former Accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedures, which disagreements if not resolved to the satisfaction of the Former Accountant would have caused them to
make reference thereto in their reports on the financial statements for such periods.
During the fiscal years ended September 30, 2017 and 2016, and through
the interim period ended May 31, 2019, there were the following “reportable events” (as such term is defined in Item
304 of Regulation S-K). As disclosed in Part I, Item 4 of the Company’s Form 10-Q for the quarter ended March 31, 2018, the
Company’s management determined that the Company’s internal controls over financial reporting were not effective as
of the end of such period due to the existence of material weaknesses related to the following:
|
(i)
|
inadequate segregation of duties and effective risk assessment; and
|
|
(ii)
|
insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application
of both US GAAP and SEC guidelines.
|
These material weaknesses have not been remediated as of the date
of this Current Report on Form 8-K.
Other than as disclosed above, there were no reportable events during
the fiscal years ended September 30, 2017 and 2016, and through the interim period ended May 31, 2019. The Company’s Board
of Directors discussed the subject matter of each reportable event with the Former Accountant. The Company authorized the Former
Accountant to respond fully and without limitation to all requests of the New Accountant concerning all matters related to the
audited period by the Former Accountant, including with respect to the subject matter of each reportable event.
On June 19, 2019, the Company provided the Former Accountant with
its disclosures in the Current Report on Form 8-K disclosing the dismissal of the Former Accountant and requested in writing that
the Former Accountant furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or
not they agree with such disclosures. The Former Accountant’s response is filed as an exhibit to this Current Report on Form
8-K.
SECTION
9 –
Financial Statements and ExhibiTS
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Alterola
Biotech, Inc.
/s/
Peter Maddocks
Peter Maddocks
Chief
Executive Officer
Date:
June 21, 2019